Targeting the prostate-specific membrane antigen for prostate cancer therapy

Immunotherapy

Volumn 1, Issue 3, 2009, Pages 471-481

  Bühler, Patrick ^a   Wolf, Philipp ^a   Elsässer Beile, Ursula ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Immunotherapy; Prostate cancer; Prostate specific membrane antigen; PSMA vaccine; Radiotherapy; Targeted toxin

Indexed keywords

DNA VACCINE; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 7E11; MONOCLONAL ANTIBODY J591; PLASMID DNA; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG;

CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CYTOKINE PRODUCTION; DNA IMMUNIZATION; DRUG TARGETING; HUMAN; IMMUNOHISTOCHEMISTRY; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; RADIOIMMUNOTHERAPY; REVIEW;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIGENS, NEOPLASM; ANTIGENS, SURFACE; CARCINOMA; EPITHELIAL CELLS; GENE EXPRESSION PROFILING; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; LYMPHOCYTE ACTIVATION; MALE; PROSTATIC NEOPLASMS; RADIOIMMUNODETECTION; T-LYMPHOCYTES, CYTOTOXIC;

EID: 77950401374     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/imt.09.17     Document Type: Review

References (102)

1. Jemal A, Siegel R, Ward E et al.: Cancer statistics, 2008. CA Cancer J. Clin. 58, 71-96 (2008).
2. Miyamoto H, Messing EM, Chang C: Androgen deprivation therapy for prostate cancer: current status and future prospects. Prostate 61, 332-353 (2004). (Pubitemid 39571710)
3. de Wit R: Chemotherapy in hormone-refractory prostate cancer. BJU Int. 101(Suppl. 2), 11-15 (2008).
4. O'Keefe DS, Su SL, Bacich DJ et al.: Mapping, genomic organization and promoter analysis of the human prostate-specific membrane antigen gene. Biochim. Biophys. Acta 1443, 113-127 (1998).
5. Davis MI, Bennett MJ, Thomas LM, Bjorkman PJ: Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase. Proc. Natl Acad. Sci. USA 102, 5981-5986 (2005). ■ Fundamental work exploring the structure of prostate-specific membrane antigen (PSMA).
6. Mesters JR, Barinka C, Li W et al.: Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer. EMBO J. 25, 1375-1384 (2006).
7. Barinka C, Sacha P, Sklenar J et al.: Identification of the N-glycosylation sites on glutamate carboxypeptidase II necessary for proteolytic activity. Protein Sci. 13, 1627-1635 (2004). (Pubitemid 38669250)
8. Rawlings ND, Barrett AJ: Structure of membrane glutamate carboxypeptidase. Biochim. Biophys. Acta 1339, 247-252 (1997).
9. Israeli RS, Powell CT, Fair WR, Heston WD: Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res. 53, 227-230 (1993).
10. Rajasekaran AK, Anilkumar G, Christiansen JJ: Is prostate-specific membrane antigen a multifunctional protein? Am. J. Physiol. Cell Physiol. 288, C975-C981 (2005).
11. Liu H, Rajasekaran AK, Moy P et al.: Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res. 58, 4055-4060 (1998). (Pubitemid 28440554)
12. Rajasekaran SA, Anilkumar G, Oshima E et al.: A novel cytoplasmic tail MXXXL motif mediates the internalization of prostate-specific membrane antigen. Mol. Biol. Cell. 14, 4835-4845 (2003).
13. Anilkumar G, Rajasekaran SA, Wang S, Hankinson O, Bander NH, Rajasekaran AK: Prostate-specific membrane antigen association with filamin A modulates its internalization and NAALADase activity. Cancer Res. 63, 2645-2648 (2003). (Pubitemid 36605208)
14. Ghosh A, Heston WD: Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J. Cell Biochem. 91, 528-539 (2004).
15. Horoszewicz JS, Kawinski E, Murphy GP: Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res. 7, 927-935 (1987). (Pubitemid 18036141)
16. Troyer JK, Beckett ML, Wright GL Jr: Location of prostate-specific membrane antigen in the LNCaP prostate carcinoma cell line. Prostate 30, 232-242 (1997).
17. Schulke N, Varlamova OA, Donovan GP et al.: The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy. Proc. Natl Acad. Sci. USA 100, 12590-12595 (2003). ■■ Essential work for anti-PSMA monoclonal antibody (mAb) development.
18. Liu H, Moy P, Kim S et al.: Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res. 57, 3629-3634 (1997). ■■ Presentation of the first conformational mAb against cell-adherent PSMA. (Pubitemid 27381196)
19. Bander NH, Nanus DM, Milowsky MI, Kostakoglu L, Vallabahajosula S, Goldsmith SJ: Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen. Semin. Oncol. 30, 667-676 (2003).
20. Brown LG, Wegner SK, Wang H et al.: A novel monoclonal antibody 107-1A4 with high prostate specificity: generation, characterization of antigen expression, and targeting of human prostate cancer xenografts. Prostate Cancer Prostatic Dis. 1, 208-215 (1998). (Pubitemid 128545867)
21. Wang S, Diamond DL, Hass GM, Sokoloff R, Vessella RL: Identification of prostate specific membrane antigen (PSMA) as the target of monoclonal antibody 107-1A4 by proteinchip; array, surface-enhanced laser desorption/ionization (SELDI) technology. Int. J. Cancer 92, 871-876 (2001). (Pubitemid 32467378)
22. Murphy GP, Greene TG, Tino WT, Boynton AL, Holmes EH: Isolation and characterization of monoclonal antibodies specific for the extracellular domain of prostate specific membrane antigen. J. Urol. 160, 2396-2401 (1998).
23. Grauer LS, Lawler KD, Marignac JL, Kumar A, Goel AS, Wolfert RL: Identification, purification, and subcellular localization of prostate-specific membrane antigen PSM' protein in the LNCaP prostatic carcinoma cell line. Cancer Res. 58, 4787-4789 (1998). (Pubitemid 28503668)
24. Fracasso G, Bellisola G, Cingarlini S et al.: Anti-tumor effects of toxins targeted to the prostate specific membrane antigen. Prostate 53, 9-23 (2002). (Pubitemid 34966860)
25. Huang X, Bennett M, Thorpe PE: Anti-tumor effects and lack of side effects in mice of an immunotoxin directed against human and mouse prostate-specific membrane antigen. Prostate 61, 1-11 (2004). (Pubitemid 39095691)
26. Kinoshita Y, Kuratsukuri K, Newman N et al.: Targeting epitopes in prostate-specific membrane antigen for antibody therapy of prostate cancer. Prostate Cancer Prostatic Dis. 8, 359-363 (2005). (Pubitemid 43078172)
27. Elsässer-Beile U, Wolf P, Gierschner D, Bühler P, Schultze-Seemann W, Wetterauer U: A new generation of monoclonal and recombinant antibodies against cell-adherent prostate specific membrane antigen for diagnostic and therapeutic targeting of prostate cancer. Prostate 66, 1359-1370 (2006). ■ Comparison of linear and conformational anti-PSMA mAbs. (Pubitemid 44350361)
28. Moffett S, Melancon D, DeCrescenzo G et al.: Preparation and characterization of new anti-PSMA monoclonal antibodies with potential clinical use. Hybridoma (Larchmt.) 26, 363-372 (2007).
29. Sweat SD, Pacelli A, Murphy GP, Bostwick DG: Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology 52, 637-640 (1998). (Pubitemid 28440171)
30. Wright GL, Haley C, Beckett ML, Schellhammer PF: Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urol. Oncol. 1, 18-28 (1995).
31. Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP: Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer 82, 2256-2261 (1998). (Pubitemid 28240834)
32. Ross JS, Sheehan CE, Fisher HA et al.: Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin. Cancer Res. 9, 6357-6362 (2003).
33. Kinoshita Y, Kuratsukuri K, Landas S et al.: Expression of prostate-specific membrane antigen in normal and malignant human tissues. World J. Surg. 30, 628-636 (2006).
34. Burger MJ, Tebay MA, Keith PA et al.: Expression analysis of δ-catenin and prostate-specific membrane antigen: their potential as diagnostic markers for prostate cancer. Int. J. Cancer 100, 228-237 (2002).
35. Cao KY, Mao XP, Wang DH et al.: High expression of PSM-E correlated with tumor grade in prostate cancer: a new alternatively spliced variant of prostate-specific membrane antigen. Prostate 67, 1791 - 1800 (2007).
36. Chang SS, Reuter VE, Heston WD, Bander NH, Grauer LS, Gaudin PB: Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res. 59, 3192-3198. (1999).
37. Lopes AD, Davis WL, Rosenstraus MJ, Uveges AJ, Gilman SC: Immunohistochemical and pharmacokinetic characterization of the site-specific immunoconjugate CYT-356 derived from antiprostate monoclonal antibody 7E11-C5. Cancer Res. 50, 6423-6429 (1990).
38. Zhang S, Zhang HS, Reuter VE, Slovin SF, Scher HI, Livingston PO: Expression of potential target antigens for immunotherapy on primary and metastatic prostate cancers. Clin. Cancer Res. 4, 295-302 (1998).
39. Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C: Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin. Cancer Res. 3, 81-85 (1997).
40. Troyer JK, Beckett ML, Wright GL Jr: Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int. J. Cancer 62, 552-558 (1995).
41. Mhawech-Fauceglia P, Zhang S, Terracciano L et al.: Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using mutiple tumour tissue microarray technique. Histopathobgy 50, 472-483 (2007). (Pubitemid 46328190)
42. Murphy GP, Su S, Jarisch J, Kenny GM: Serum levels of PSMA. Prostate 42, 318-319 (2000).
43. Sokoloff RL, Norton KC, Gasior CL, Marker KM, Grauer LS: A dual-monoclonal sandwich assay for prostate-specific membrane antigen: levels in tissues, seminal fluid and urine. Prostate 43, 150-157 (2000).
44. O'Keefe DS, Bacich DJ, Heston WD: Comparative analysis of prostate-specific membrane antigen (PSMA) versus a prostate-specific membrane antigen-like gene. Prostate 58, 200-210 (2004).
45. Sacha P, Zamecnik J, Barinka C et al.: Expression of glutamate carboxypeptidase II in human brain. Neuroscience 144, 1361-1372 (2007). (Pubitemid 46123795)
46. Chang SS, O'Keefe DS, Bacich DJ, Reuter VE, Heston WD, Gaudin PB: Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin. Cancer Res. 5, 2674-2681 (1999).
47. Conway RE, Petrovic N, Li Z, Heston W, Wu D, Shapiro LH: Prostate-specific membrane antigen regulates angiogenesis by modulating integrin signal transduction. Mol. Cell Biol. 26, 5310-5324 (2006).
48. Russell PJ, Hewish D, Carter T et al.: Cytotoxic properties of immunoconjugates containing melittin-like peptide 101 against prostate cancer: in vitro and in vivo studies. Cancer Immunol. Immunother. 53, 411-421 (2004).
49. Ma D, Hopf CE, Malewicz AD et al.: Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen. Clin. Cancer Res. 12, 2591-2596 (2006).
50. Henry MD, Wen S, Silva MD, Chandra S, Milton M, Worland PJ: A prostate-specific membrane antigen-targeted monoclonal antibody-chemotherapeutic conjugate designed for the treatment of prostate cancer. Cancer Res. 64, 7995-8001 (2004). (Pubitemid 39446934)
51. Galsky MD, Eisenberger M, Moore-Cooper S et al.: Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer. J. Clin. Oncol. 26, 2147-2154 (2008).
52. Wolf P, Gierschner D, Bühler P, Wetterauer U, Elsässer-Beile U: A recombinant PSMA-specific single-chain immunotoxin has potent and selective toxicity against prostate cancer cells. Cancer Immunol. Immunother. 55, 1367-1373 (2006).
53. Wolf P, Alt K, Bühler P et al.: Anti-PSMA immunotoxin as novel treatment for prostate cancer? High and specific antitumor activity on human prostate xenograft tumors in SCID mice. Prostate 68, 129-138 (2008). ■ First recombinant anti-PSMA immunotoxin. (Pubitemid 351186225)
54. Aggarwal S, Singh P, Topaloglu O, Isaacs JT, Denmeade SR: A dimeric peptide that binds selectively to prostate-specific membrane antigen and inhibits its enzymatic activity. Cancer Res. 66, 9171-9177 (2006). (Pubitemid 44521137)
55. Lupold SE, Hicke BJ, Lin Y, Coffey DS: Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen. Cancer Res. 62, 4029-4033 (2002). (Pubitemid 34791070)
56. Chu TC, Marks JW 3rd, Lavery LA et al.: Aptamer:toxin conjugates that specifically target prostate tumor cells. Cancer Res. 66, 5989-5992 (2006).
57. Farokhzad OC, Cheng J, Teply BA et al.: Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc. Natl Acad. Sci. USA 103, 6315-6320 (2006). ■ New, specific anti-PSMA therapy.
58. Gu F, Zhang L, Teply BA et al.: Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc. Natl Acad. Sci. USA 105, 2586-2591 (2008).
59. Dhar S, Gu FX, Langer R, Farokhzad OC, Lippard SJ: Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA-PEG nanoparticles. Proc. Natl Acad. Sci. USA 105, 17356-17361 (2008).
60. Jayaprakash S, Wang X, Heston WD, Kozikowski AP: Design and synthesis of a PSMA inhibitor-doxorubicin conjugate for targeted prostate cancer therapy. Chem. Med. Chem. 1, 299-302 (2006).
61. Liu T, Wu LY, Kazak M, Berkman CE: Cell-surface labeling and internalization by a fluorescent inhibitor of prostate-specific membrane antigen. Prostate 68, 955-964 (2008). (Pubitemid 351794160)
62. Liu T, Wu LY, Choi JK, Berkman CE: In vitro targeted photodynamic therapy with a pyropheophorbide - a conjugated inhibitor of prostate-specific membrane antigen. Prostate 69(6), 585-594 (2009).
63. 111indium labeled CYT-356 for the detection of occult prostate cancer recurrence. J. Urol. 152, 1490-1495 (1994). (Pubitemid 2153749)
64. Sodee DB, Conant R, Chalfant M et al.: Preliminary imaging results using In-111 labeled CYT-356 (Prostascint) in the detection of recurrent prostate cancer. Clin. Nucl. Med. 21, 759-767 (1996).
65. Haseman MK, Reed NL, Rosenthal SA: Monoclonal antibody imaging of occult prostate cancer in patients with elevated prostate-specific antigen. Positron emission tomography and biopsy correlation. Clin. Nucl. Med. 21, 704-713 (1996).
66. 111Indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy. The ProstaScint® Study Group. J. Urol. 159, 2041-2046; discussion 2046-2047 (1998). (Pubitemid 29190751)
67. Seltzer MA, Barbaric Z, Belldegrun A et al.: Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer. J. Urol. 162, 1322-1328 (1999). (Pubitemid 29428572)
68. Murphy GP, Elgamal AA, Su SL, Bostwick DG, Holmes EH: Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen. Cancer 83, 2259-2269 (1998).
69. 90yttrium-capromab pendetide in the treatment of men with prostate cancer recurrence following radical prostatectomy. Cancer Biother. Radiopharm. 14, 99-111 (1999).
70. 90Y-CYT-356 monoclonal antibody. Clin. Cancer Res. 2, 1289-1297 (1996).
71. Sodee DB, Sodee AE, Bakale G: Synergistic value of single-photon emission computed tomography/computed tomography fusion to radioimmunoscintigraphic imaging of prostate cancer. Semin. Nucl. Med. 37, 17-28 (2007).
72. 213BiJ591) for radioimmunotherapy of prostate cancer. Cancer Res. 60, 6095-6100 (2000). (Pubitemid 30842123)
73. Smith-Jones PM, Vallabhajosula S, Navarro V, Bastidas D, Goldsmith SJ, Bander NH: Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor. J. Nucl. Med. 44, 610-617 (2003).
74. Vallabhajosula S, Smith-Jones PM, Navarro V, Goldsmith SJ, Bander NH: Radioimmunotherapy of prostate cancer in human xenografts using monoclonal antibodies specific to prostate specific membrane antigen (PSMA): studies in nude mice. Prostate 58, 145-155 (2004). (Pubitemid 38160901)
75. Elsässer-Beile U, Reischl G, Wiehr S et al.: PET imaging of prostate cancer xenografts with a highly specific antibody against the prostate-specific membrane antigen. J. Nucl. Med. (2009) (In press).
76. Bander NH, Trabulsi EJ, Kostakoglu L et al.: Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. J. Urol. 170, 1717-1721 (2003). (Pubitemid 37254913)
77. Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ, Bander NH: Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J. Clin. Oncol. 22, 2522-2531 (2004).
78. 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J. Clin. Oncol. 23, 4591-4601 (2005). • Clinical study on anti-PSMA radiotherapy.
79. 177Lu? J. Nucl. Med. 46, 634-641 (2005).
80. 177Lu-labeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicity. Clin Cancer Res. 11, 7195S-7200S (2005). (Pubitemid 41428723)
81. Nanus DM, Milowsky MI, Kostakoglu L et al.: Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen. J. Urol. 170, S84-S88; discussion S88-S89 (2003). (Pubitemid 37413948)
82. Morris MJ, Divgi CR, Pandit-Taskar N et al.: Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer. Clin. Cancer Res. 11, 7454-7461 (2005).
83. Morris MJ, Pandit-Taskar N, Divgi CR et al.: Phase I evaluation of J591 as a vascular targeting agent in progressive solid tumors. Clin. Cancer Res. 13, 2707-2713 (2007).
84. Milowsky MI, Nanus DM, Kostakoglu L et al.: Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. J. Clin. Oncol. 25, 540-547 (2007).
85. Bühler P, Wolf P, Gierschner D et al.: A bispecific diabody directed against prostate-specific membrane antigen and CD3 induces T-cell mediated lysis of prostate cancer cells. Cancer Immunol. lmmunother. 57, 43-52 (2008).
86. Gong MC, Latouche JB, Krause A, Heston WD, Bander NH, Sadelain M: Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. Neoplasia 1, 123-127 (1999).
87. Gade TP, Hassen W, Santos E et al.: Targeted elimination of prostate cancer by genetically directed human T lymphocytes. Cancer Res. 65, 9080-9088 (2005). (Pubitemid 41377401)
88. Maher J, Brentjens RJ, Gunset G, Riviere I, Sadelain M: Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRζ/CD28 receptor. Nat. Biotechnol. 20, 70-75 (2002).
89. Ma Q, Safar M, Holmes E, Wang Y, Boynton AL, Junghans RP: Anti-prostate specific membrane antigen designer T cells for prostate cancer therapy. Prostate 61, 12-25 (2004). ■ New and interesting retargeting therapy. (Pubitemid 39095692)
90. Tjoa BA, Simmons SJ, Bowes VA et al.: Evaluation of Phase I/II clinical trials in prostate cancer with dendritic cells and PSMA peptides. Prostate 36, 39-44 (1998).
91. Murphy GP, Tjoa BA, Simmons SJ et al.: Infusion of dendritic cells pulsed with HLA-A2-specific prostate-specific membrane antigen peptides: a Phase II prostate cancer vaccine trial involving patients with hormone-refractory metastatic disease. Prostate 38, 73-78 (1999).
92. Murphy GP, Tjoa BA, Simmons SJ et al.: Phase II prostate cancer vaccine trial: report of a study involving 37 patients with disease recurrence following primary treatment. Prostate 39, 54-59 (1999).
93. Tjoa BA, Simmons SJ, Elgamal A et al.: Follow-up evaluation of a Phase II prostate cancer vaccine trial. Prostate 40, 125-129 (1999). (Pubitemid 29244504)
94. Salgaller ML, Lodge PA, McLean JG et al.: Report of immune monitoring of prostate cancer patients undergoing T-cell therapy using dendritic cells pulsed with HLA-A2-specific peptides from prostate-specific membrane antigen (PSMA). Prostate 35, 144-151 (1998).
95. Lodge PA, Jones LA, Bader RA, Murphy GP, Salgaller ML: Dendritic cell-based immunotherapy of prostate cancer: immune monitoring of a Phase II clinical trial. Cancer Res. 60, 829-833 (2000).
96. Mincheff M, Zoubak S, Altankova I et al.: Human dendritic cells genetically engineered to express cytosolically retained fragment of prostate-specific membrane antigen prime cytotoxic T-cell responses to multiple epitopes. Cancer Gene Ther. 10, 907-917 (2003). (Pubitemid 37532337)
97. Mincheff M, Tchakarov S, Zoubak S et al.: Naked DNA and adenoviral immunizations for immunotherapy of prostate cancer: a Phase I/II clinical trial. Eur. Urol. 38, 208-217 (2000).
98. Todorova K, Ignatova I, Tchakarov S et al.: Humoral immune response in prostate cancer patients after immunization with gene-based vaccines that encode for a protein that is proteasomally degraded. Cancer Immun. 5, 1-8 (2005). (Pubitemid 40300852)
99. Gregor PD, Wolchok JD, Turaga V et al.: Induction of autoantibodies to syngeneic prostate-specific membrane antigen by xenogeneic vaccination. Int. J. Cancer 116, 415-421 (2005). (Pubitemid 40993338)
100. Mincheff M, Zoubak S, Makogonenko Y: Immune responses against PSMA after gene-based vaccination for immunotherapy-A: results from immunizations in animals. Cancer Gene Ther. 13, 436-444 (2006).
101. Gregor P, Wolchok J, Pedraza A et al.: A xenogenic PSMA DNA vaccine for patients with non-castrate metastatic and castrate metastatic prostate cancer: a Phase I trial of proof of principle. Program and Abstracts of the ASCO Prostate Cancer Symposium 2007: Updates on Prostate Cancer. Orlando, FL, USA 22-24 February (2007) (Abstract 260).
102. Durso RJ, Andjelic S, Gardner JP et al.: A novel alphavirus vaccine encoding prostate-specific membrane antigen elicits potent cellular and humoral immune responses. Clin. Cancer Res. 13, 3999-4008 (2007).